Hims & Hers Health ( (HIMS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Hims & Hers Health stock is jumping as traders latch onto a fresh $32 price target from JPMorgan, which points to the company potentially raking in $1.1 billion in GLP-1 weight-loss revenues by 2026. The rally is getting another boost from the launch of a new 3x leveraged long product on the London Stock Exchange, drawing in momentum-driven retail and institutional buyers who see the telehealth player’s pivot to branded weight-loss drugs as a major growth leg.
For longer-term investors, the company’s rapid revenue gains and nearly three million subscribers suggest a growing, sticky customer base that could support recurring sales and better efficiency as Hims & Hers adds new conditions and markets. However, rising debt and pressure on profit margins from lower-margin weight-loss and international offerings mean the company has less room for error, and any stumble in execution or new regulatory hurdles could hit future earnings and slow its expansion plans.
More about Hims & Hers Health
YTD Price Performance: -15.28%
Average Trading Volume: 14,271,815
Technical Sentiment Signal: Sell
Current Market Cap: $6.42B
For further insights into HIMS stock on
TipRanks’ Stock Analysis page.
See more of today’s
top stock gainers and losers.


